KRAS ^G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8 ⁺ T cells.

Autor: Mahadevan KK; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., McAndrews KM; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., LeBleu VS; Feinberg School of Medicine and Kellogg School of Management, Northwestern University, Chicago, IL, USA., Yang S; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lyu H; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li B; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sockwell AM; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kirtley ML; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Morse SJ; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moreno Diaz BA; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim MP; Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feng N; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lopez AM; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Guerrero PA; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Break Through Cancer, Cambridge, MA, USA., Paradiso F; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sugimoto H; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Arian KA; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ying H; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Barekatain Y; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sthanam LK; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kelly PJ; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maitra A; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: amaitra@mdanderson.org., Heffernan TP; TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: tpheffernan@mdanderson.org., Kalluri R; Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Bioengineering, Rice University, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. Electronic address: rkalluri@mdanderson.org.

Publikováno v: Cancer cell [Cancer Cell] 2023 Sep 11; Vol. 41 (9), pp. 1606-1620.e8. Date of Electronic Publication: 2023 Aug 24.

Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma.

Autor: Haltom AR; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX., Hassen WE; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX., Hensel J; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX., Kim J; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX., Sugimoto H; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX., Li B; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX., McAndrews KM; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX., Conner MR; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX., Kirtley ML; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX., Luo X; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Bioengineering, Rice University, Houston, TX., Xie B; Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL., Volpert OV; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX., Olalekan S; Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL., Maltsev N; Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL., Basu A; Section of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, IL., LeBleu VS; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX.; Feinberg School of Medicine & Kellogg School of Management, Northwestern University, Chicago, IL., Kalluri R; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX.; James P. Allison Institute at MD Anderson, Houston, TX.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.; Department of Bioengineering, Rice University, Houston, TX.

Publikováno v: Extracellular vesicle [Extracell Vesicle] 2022 Dec; Vol. 1. Date of Electronic Publication: 2022 Oct 27.

αSMA ⁺ fibroblasts suppress Lgr5 ⁺ cancer stem cells and restrain colorectal cancer progression.

Autor: McAndrews KM; Metastasis Research Center, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vázquez-Arreguín K; Metastasis Research Center, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kwak C; Metastasis Research Center, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sugimoto H; Metastasis Research Center, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zheng X; Metastasis Research Center, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li B; Metastasis Research Center, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kirtley ML; Metastasis Research Center, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., LeBleu VS; Metastasis Research Center, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Kalluri R; Metastasis Research Center, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. rkalluri@mdanderson.org.; Department of Bioengineering, Rice University, Houston, TX, USA. rkalluri@mdanderson.org.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. rkalluri@mdanderson.org.

Publikováno v: Oncogene [Oncogene] 2021 Jul; Vol. 40 (26), pp. 4440-4452. Date of Electronic Publication: 2021 Jun 09.

Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics.

Autor: Andersson JA; Institute for Translational Sciences, University of Texas Medical Branch, Galveston, Texas, USA., Sha J; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA., Kirtley ML; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Reyes E; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Fitts EC; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Dann SM; Institute for Translational Sciences, University of Texas Medical Branch, Galveston, Texas, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA.; Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.; Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA., Chopra AK; Institute for Translational Sciences, University of Texas Medical Branch, Galveston, Texas, USA achopra@utmb.edu.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA.; WHO Collaborating Center for Vaccine Development, University of Texas Medical Branch, Galveston, Texas, USA.; Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2017 Dec 21; Vol. 62 (1). Date of Electronic Publication: 2017 Dec 21 (Print Publication: 2018).

A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis .

Autor: Tao P; Department of Biology, The Catholic University of America, Washington, DC, United States., Mahalingam M; Department of Biology, The Catholic University of America, Washington, DC, United States., Zhu J; Department of Biology, The Catholic University of America, Washington, DC, United States., Moayeri M; Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States., Kirtley ML; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States., Fitts EC; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States., Andersson JA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States., Lawrence WS; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, United States., Leppla SH; Microbial Pathogenesis Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States., Chopra AK; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, United States.; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, United States.; Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, United States.; Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, United States., Rao VB; Department of Biology, The Catholic University of America, Washington, DC, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2017 Jun 26; Vol. 8, pp. 687. Date of Electronic Publication: 2017 Jun 26 (Print Publication: 2017).